
|Videos|March 10, 2015
Trial Designs in Ovarian Cancer
Author(s)Jason D. Wright, MD
Jason D. Wright, MD, from Columbia University, discusses clinical trial designs in ovarian cancer.
Advertisement
Clinical Pearls
Jason D. Wright, MD, Division Chief, Gynecologic Oncology, Associate Clinical Professor of Gynecologic Oncology, Sol Goldman Associate Professor of Obstetrics and Gynecology, Columbia University, discusses clinical trial designs in ovarian cancer.
- Many patients with ovarian cancer receive a variety of off-label therapies. Nevertheless, overall survival has improved.
- The ovarian cancer community must weigh the pros and cons of a sound trial design with its application in the real world.
- Progression-free survival has its limitations but is probably the most reasonable trial endpoint.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
5








































